# Elucid Bioimaging Inc.: Form D capital raise (Boston, MA)

**Vendor Spend Propensity Score (CPA / Tax / Audit):** 68/100
**Estimated post-raise budget for this service type:** $1,124,700 (heuristic)

| Field | Value |
|---|---|
| Industry | Biotechnology (Healthcare & Life Sciences) |
| Operating company | Yes |
| Exemption | 506(b) |
| Amount sold | $56,235,000 |
| Total offering | $79,999,999 |
| Investors so far | 20 |
| First sale | 2025-10-10 |
| Filed | 2026-10-27 (amendment) |
| Entity | Corporation |

## Executives and related persons (as listed in the filing)
- Blake Richards: Executive Officer
- Scott Huennekens: Director
- Michael Lesh: Director
- Richard Kuntz: Director
- Evan Melrose: Director
- Shamiram Feinglass: Director
- Kelly Huang: Executive Officer, Director
- Rajesh Panda: Director

## Why this score
- Operating company: new capital typically funds hiring, facilities and vendors.
- Raised $56,235,000 so far: a large raise.
- Healthcare & Life Sciences companies are a strong fit for CPA / Tax / Audit services.

Source: SEC EDGAR Form D filings (U.S. Securities and Exchange Commission) (https://www.sec.gov/Archives/edgar/data/1585931/000208061226000057/). Last refreshed: 2026-11-04T15:17:01.911Z.
Informational only. SEC EDGAR Form D data is shown for business-development research; it is not investment advice and not an offer or solicitation to buy or sell any security. Not legal or financial advice.